Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
19.14
-0.35 (-1.80%)
At close: Jan 17, 2025, 4:00 PM
19.00
-0.14 (-0.73%)
After-hours: Jan 17, 2025, 6:04 PM EST
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $12.59M in the quarter ending August 31, 2024, a decrease of -31.84%. This brings the company's revenue in the last twelve months to $56.42M, down -17.76% year-over-year. In the fiscal year ending November 30, 2023, Nurix Therapeutics had annual revenue of $76.99M with 99.31% growth.
Revenue (ttm)
$56.42M
Revenue Growth
-17.76%
P/S Ratio
20.76
Revenue / Employee
$198,676
Employees
284
Market Cap
1.36B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
NRIX News
- 11 days ago - Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation - Seeking Alpha
- 14 days ago - Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting - GlobeNewsWire
- 7 weeks ago - Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 2 months ago - Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - GlobeNewsWire